Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12426830 | 0.83 | ALDH1A1 (0.41) | SMN1; SMN2RAB9ANPC1CYP2C9TSHR | |
| SCHEMBL2818700 | 0.81 | MAPT (0.42) | SMN1; SMN2TSHRKMT2AALDH1A1MAPT | |
| SCHEMBL6359211 | 0.81 | MAPT (0.40) | SMN1; SMN2RAB9ANPC1RECQLKMT2A | |
| SCHEMBL6784448 | 0.81 | SMN1; SMN2 (0.38) | SMN1; SMN2RAB9ANPC1RECQLCYP2D6 | |
| SCHEMBL6364141 | 0.80 | ALDH1A1 (0.43) | SMN1; SMN2RAB9ANPC1RECQLKMT2A | |
| SCHEMBL3284462 | 0.80 | ALDH1A1 (0.46) | SMN1; SMN2CYP2C9TSHRCYP2C19KMT2A | |
| SCHEMBL5727003 | 0.80 | CHRNA1 (0.37) | SMN1; SMN2RAB9ANPC1RECQLTSHR | |
| SCHEMBL2823545 | 0.79 | CA1 (0.44) | SMN1; SMN2RAB9ATSHRKMT2AMEN1 | |
| SCHEMBL4884087 | 0.79 | SLC22A12 (0.44) | SLC22A12ALDH1A1MAPT | |
| SCHEMBL4877710 | 0.79 | LOXL2 (0.40) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713971-B2 | 1,2,4-triazine derivatives, preparation and use thereof in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2010-05-11 | — | — | US | disclosed |
| US-7528276-B2 | Process for preparing the intermediate compounds for PPAR α ligands | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2009-05-05 | — | — | US | disclosed |
| US-7528276-B2 | Process for preparing the intermediate compounds for PPAR α ligands | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2009-05-05 | — | — | US | disclosed |
| US-7528276-B2 | Process for preparing the intermediate compounds for PPAR α ligands | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2009-05-05 | — | — | US | disclosed |
| US-20090062358-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | CANO IVAN COLLADO | 2009-03-05 | — | — | US | disclosed |
| US-20080269516-A1 | Process for Preparing the Intermediate Compounds for Pparalpha Ligands | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2008-10-30 | — | — | US | disclosed |
| US-20080269516-A1 | Process for Preparing the Intermediate Compounds for Pparalpha Ligands | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2008-10-30 | — | — | US | disclosed |
| US-20080269516-A1 | Process for Preparing the Intermediate Compounds for Pparalpha Ligands | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2008-10-30 | — | — | US | disclosed |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | PIERRE FABRE MEDICAMENT (FR) | 2008-07-10 | — | — | US | disclosed |
| EP-1335908-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | LILLY CO ELI (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1328508-A2 | PROPIONIC ACID DERIVATIVES WITH PPAR-ALPHA ACTIVATING PROPERTIES | Bayer Aktiengesellschaft (DE) | 2003-07-23 | — | — | EP | disclosed |
| WO-2003037332-A1 | PHENYL SUBSTITUTED 5-MEMBERED NITROGEN CONTAINING HETEROCYCLES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003035603-A1 | ACETIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-05-01 | — | — | WO | disclosed |
| US-6548538-B2 | Potent peroxisome proliferator activated receptor (PPAR)-alpha-activating compounds; propionic acid 2-subsituted with an N-(phenylaminocarbonylalkyl), N-(2-furanylmethyl)aminoalkylphenyl group | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-15 | — | — | US | disclosed |
| US-20030032671-A1 | Propionic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-02-13 | — | — | US | disclosed |
| WO-2002038553-A2 | TRIAZOLE DERIVATIVES AND THEIR USE AS PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | ELI LILLY AND COMPANY (US) | 2002-05-16 | — | — | WO | disclosed |
| WO-2002028821-A2 | PROPIONIC ACID DERIVATIVES WITH PPAR-ALPHA ACTIVATING PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-04-11 | — | — | WO | disclosed |
| EP-1149063-A2 | UREIDO-THIOBUTYRIC ACID DERIVATIVES AS PPAR-AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-10-31 | — | — | EP | disclosed |
| US-6306854-B1 | ARYLTHIOALKYLACIDS AND ALKYL UREAS | GLAXOSMITHKLINE | 2001-10-23 | — | — | US | disclosed |
| WO-2000023407-A2 | UREIDO-THIOBUTYRIC ACID DERIVATIVES AS PPAR-AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269516-A1 | Process for Preparing the Intermediate Compounds for Pparalpha Ligands | PPARG, PPARA, PPARD | SMN1; SMN2 4766/4885RAB9A 3368/4885NPC1 551/4885 |
| US-20030032671-A1 | Propionic acid derivatives | PPARD, PPARA, PPARG | SMN1; SMN2 4633/4885RAB9A 2787/4885NPC1 2557/4885 |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | CBR3, NOX3, RTN3 | SMN1; SMN2 1291/4885RAB9A 2897/4885NPC1 1055/4885 |
| US-20090062358-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | PPARG, PPARA, PPARD | SMN1; SMN2 4364/4885RAB9A 4445/4885NPC1 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.